Stanford researchers have discovered RNA signatures that can be used to predict patient outcomes and identify optimal treatments in acute myeloid leukemia.
Engineered cytotoxic T cells are a promising class of cell therapies. These living drugs are capable of selectively killing blood cancers, such as acute myeloid leukemia (AML), and delaying its progression.